{
    "title": "114_hr971",
    "content": "The Act titled \"Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015\" extends exclusivity periods for drugs approved for new indications for rare diseases or conditions. The Act \"Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015\" allows the Secretary to designate a drug for a new indication to prevent, diagnose, or treat a rare disease, granting extensions if certain conditions are met. The Act allows the Secretary to designate a drug for a new indication to prevent, diagnose, or treat a rare disease, granting extensions if specific conditions are met, including a request for designation, consent to notice, and a list of relevant patents. The Act allows the Secretary to designate a drug for a new indication to prevent, diagnose, or treat a rare disease, granting extensions if specific conditions are met, including a request for designation, consent to notice, and a list of relevant patents. The designation of a drug under this subsection cannot be revoked except under specific circumstances outlined by the Secretary. The Secretary can designate a drug for a new indication to prevent, diagnose, or treat a rare disease. The sponsor must notify the Secretary of any discontinuance of drug production for commercial reasons at least one year in advance. Public notice of the drug designation must include patent listings. If the Secretary designates a drug for a new indication for a rare disease, certain periods related to drug approval will be extended by 6 months. If a drug designated for a new indication for a rare disease is subject to a listed patent with a certification submitted under certain sections of the law, the approval period will be extended by 6 months after the patent expires. If a drug designated for a new indication for a rare disease has a listed patent with a certification submitted under specific sections of the law, the approval period will be extended by 6 months after the patent expires. Additionally, for biological products, final approval for a biosimilar product referencing the drug will be delayed by 6 months. The approval period for a drug designated for a new indication for a rare disease will be extended by 6 months after the expiration of any listed patent. This extension is in addition to any other extensions granted for the drug. The extension for a drug designated for a new indication for a rare disease will be extended by 6 months after the expiration of any listed patent. This extension does not apply if the drug has previously received an extension. Regulations for implementing this extension must be adopted by the Secretary within 2 years of enactment. The Secretary will promulgate regulations for drug designation under subsection (a) before issuing interim guidance. Drugs meeting the criteria in subsection (a) will be designated prior to regulation promulgation. Definitions for biological product, biosimilar, and reference product are as per section 351(i) of the Public Health Service Act. Section 505F of the Federal Food, Drug, and Cosmetic Act, as added by this Act, applies to drugs approved under section 505(c) of the Act or section 351(a) of the Public Health Service Act after the enactment date. Conforming amendments are made to Section 505A regarding pediatric exclusivity for drugs. In subsection (b), a 6-month extension is added for drugs approved for a new indication for a rare disease or condition. This extension is in addition to any extensions under section 505F. Similar provisions are added in subsection (c) for drugs approved for a new indication for a rare disease or condition. The 6-month extensions in subsection (c)(1) are added for drugs approved for a new indication for a rare disease or condition, in addition to any extensions under section 505F. Amendments are made to section 505E and 351(m) regarding exclusivity for new qualified infectious disease products and pediatric exclusivity for biological products. The Public Health Service Act is amended to include a provision stating that 6-month extensions for exclusivity periods for biological products approved for a new indication for a rare disease or condition will be in addition to any extensions under section 505F."
}